Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Response and follow-up of gouty arthritis patients receiving anakinra.

From: Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases

Follow-up characteristics Anakinra for ≤3 days
Number = 23
Anakinra for >3 days
Number = 17
Response to anakinra, number (%)   
   Good 20 (87%) 16 (94%)
   Partial 2 (9%) 0 (0%)
   No response 1 (4%) 1 (6%)
Follow-up duration, months, median (IQR) 6.0 (1.5 to 14.0) 8.0 (3.0 to 13.0)
Prevention of relapse, number (%)   
   Total 17 (74%)a 13 (76%)
   Low-dose colchicine 16 (89%) 7 (54%)
   NSAIDs 3 (17%) 1 (8%)
   Steroids 1 (6%) 2 (15%)
   Anakinra 1 (6%) 9 (69%)
Relapse, number (%) 6 (26%) 7 (41%)
Delay to relapse, days, median (IQR) 15.0 (6.0 to 26.3) 60.0 (12.5 to 125.0)
Skin reaction None None
Infectious events under anakinra therapy (delay after starting anakinra) H1N1 infection (1 day) Staphylococcus aureus tophus (1 year)
S. aureus tophus (4 years)
S. aureus lung abcess (1 month)
Erysipela of the leg (2 months)
Streptococcus B urinary tract infection (1 month)
S. aureus knee arthritis (1 year)
  1. aSome patients also had different treatment. IQR, interquartile range; NSAIDs, non-steroidal anti-inflammatory drugs.